Paper9737679
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
Kiyoi H and 6 others. Leukemia, 1998. Cited by 391 papers, by iCite.
Cite this record
ConductScience Library. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Papers, record 9737679. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9737679
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid | Major topic |
| Mutation | Major topic |
| Neoplasm Proteins | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Acute Disease | |
| Animals | |
| COS Cells | |
| Chromosome Mapping | |
| Humans | |
| Myelodysplastic Syndromes | |
| Phosphorylation | |
| Receptors, Platelet-Derived Growth Factor | |
| Sequence Analysis | |
| fms-Like Tyrosine Kinase 3 |
Source PubMed
Cited by171
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 391 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42619896 | FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway. | Res Sq | 2026 | https://conductscience.org/library/papers/42619896 | PubMed |
| 42523299 | FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway. | bioRxiv | 2026 | https://conductscience.org/library/papers/42523299 | PubMed |
| 42434847 | QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. | Future Oncol | 2026 | https://conductscience.org/library/papers/42434847 | PubMed |
| 42200022 | Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42200022 | PubMed |
| 42139346 | P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML. | Sci Adv | 2026 | https://conductscience.org/library/papers/42139346 | PubMed |
| 41896977 | RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41896977 | PubMed |
| 41893037 | Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions. | J Pers Med | 2026 | https://conductscience.org/library/papers/41893037 | PubMed |
| 41082703 | Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/41082703 | PubMed |
| 41052406 | FLT3-ITD measurable residual disease from the QuANTUM-First trial. | Blood Adv | 2026 | https://conductscience.org/library/papers/41052406 | PubMed |
| 38915455 | Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia. | Mol Biol Res Commun | 2024 | https://conductscience.org/library/papers/38915455 | PubMed |
| 38495876 | Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency. | Front Immunol | 2024 | https://conductscience.org/library/papers/38495876 | PubMed |
| 37686670 | Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686670 | PubMed |
| 37606386 | Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation. | Pathophysiology | 2023 | https://conductscience.org/library/papers/37606386 | PubMed |
| 36698434 | FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile. | Onco Targets Ther | 2023 | https://conductscience.org/library/papers/36698434 | PubMed |
| 36681742 | BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells. | Leukemia | 2023 | https://conductscience.org/library/papers/36681742 | PubMed |
| 36567628 | ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD. | Mol Oncol | 2023 | https://conductscience.org/library/papers/36567628 | PubMed |
| 36532642 | Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients. | Iran J Pathol | 2022 | https://conductscience.org/library/papers/36532642 | PubMed |
| 36450475 | Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. | Intern Med | 2023 | https://conductscience.org/library/papers/36450475 | PubMed |
| 36293564 | Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36293564 | PubMed |
| 36289703 | Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. | Biomedicines | 2022 | https://conductscience.org/library/papers/36289703 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FLT3 | 2322 | Swiss-Prot's references | https://conductscience.org/library/genes/2322 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9737679
GET https://conductscience.org/api/papers/v1/9737679/cited_by?page=2